PNA5 targets Parkinson’s cognitive symptoms, may slow decline

Researchers have discovered that PNA5, an experimental therapy, may help improve memory and slow cognitive decline in Parkinson’s disease. In a study with mice, daily injections of PNA5 enhanced memory and spatial recognition, reduced brain inflammation, and protected nerve cells in the hippocampus—a brain area critical for learning and memory. PNA5, a small protein, works by activating brain receptors that reduce inflammation, increase blood flow, and protect nerve cells. When tested in a Parkinson’s mouse model, it improved performance on memory tests over two months compared to untreated mice. Cognitive decline affects many people with Parkinson’s, but there are no effective treatments yet. Researchers hope PNA5 could change that by addressing these symptoms and potentially slowing disease progression. While promising, PNA5 would likely become part of a larger treatment plan if it is successful in future studies.